
  
    
      
        Background_NNP
        Neural_NNP tube_NN defects_NNS (_( NTDs_NNP )_) are_VBP major_JJ malformations_NNS of_IN
        the_DT central_JJ nervous_JJ system_NN (_( CNS_NNP )_) due_JJ to_TO a_DT defect_NN in_IN the_DT
        covering_NN of_IN the_DT CNS_NNP ._. They_PRP are_VBP among_IN the_DT most_RBS prevalent_JJ of_IN
        congenital_NN malformations_NNS ._. NTDs_NNP are_VBP second_JJ only_RB to_TO
        congenital_NN heart_NN defects_NNS as_IN a_DT cause_NN of_IN perinatal_NN mortality_NN
        due_JJ to_TO birth_NN defect_NN and_CC range_NN in_IN incidence_NN from_IN 0_CD ._. 5_CD to_TO 12_CD
        per_IN 1000_CD live_VB births_NNS ,_, depending_VBG on_IN the_DT country_NN ,_, accounting_NN
        for_IN 400_CD ,_, 000_CD births_NNS world-wide_JJ annually_RB ._.
        Factors_NNP that_WDT predispose_VB individuals_NNS to_TO NTDs_NNP are_VBP
        numerous_JJ ._. While_IN folic_JJ acid_NN deficiency_NN and_CC altered_VBN folic_JJ
        acid_NN metabolism_NN have_VBP received_VBN widespread_JJ attention_NN ,_, other_JJ
        contributors_NNS are_VBP also_RB important_JJ ._. Socio-economic_NNP status_NN ,_,
        genetic_JJ factors_NNS ,_, maternal_NN illness_NN and_CC maternal_NN drug_NN
        exposure_NN are_VBP important_JJ contributors_NNS to_TO the_DT risk_NN of_IN
        NTDs_NNP ._.
        Drug_NN models_NNS of_IN NTDs_NNP are_VBP valued_VBN because_IN the_DT drug_NN 's_POS action_NN
        provides_VBZ a_DT possible_JJ explanation_NN of_IN the_DT pathophysiology_NN of_IN
        NTDs_NNP ._. Valproic_NNP acid_NN (_( VA_NNP )_) is_VBZ a_DT well-known_JJ teratogen_NN in_IN both_DT
        animals_NNS and_CC humans_NNS ,_, with_IN a_DT 5_CD -_: fold_VB occurrence_NN of_IN spina_NN
        bifida_NN (_( SB_NNP )_) in_IN pregnant_JJ women_NNS exposed_VBN to_TO the_DT drug_NN [_NN 1_CD ]_NN ._.
        The_DT mechanism_NN by_IN which_WDT VA_NNP produces_VBZ SB_NNP is_VBZ unknown_NN but_CC
        inhibition_NN of_IN folic_JJ acid_NN metabolism_NN is_VBZ one_CD hypothesis_NNS [_NN 2_CD 3_CD
        ]_NN ._. Some_DT investigators_NNS have_VBP brought_VBN the_DT folic_JJ acid_NN
        hypothesis_NNS into_IN question_NN by_IN demonstrating_VBG that_IN folic_JJ acid_NN
        supplementation_NN has_VBZ no_DT effect_NN on_IN VA_NNP exposed_VBD embryos_NNS
        in-vitro_JJ [_NN 4_CD 5_CD ]_NN ._. These_DT studies_NNS suggest_VBP that_IN another_DT
        mechanism_NN may_MD be_VB responsible_JJ for_IN the_DT production_NN of_IN SB_NNP by_IN
        VA_NNP ._. Other_JJ possible_JJ mechanisms_NNS include_VBP alteration_NN of_IN
        neuronal_NN membrane_NN conductance_NN ,_, sodium_NN channel_NN blockade_NN or_CC
        altered_VBN neuronal_NN calcium_NN metabolism_NN [_NN 6_CD ]_NN ._. VA_NNP is_VBZ also_RB
        known_VBN to_TO allow_VB GABA_NNP ,_, the_DT chief_JJ inhibitory_NN neurotransmitter_NN
        of_IN the_DT CNS_NNP ,_, to_TO accumulate_VBP in_IN tissues_NNS ._.
        The_DT role_NN of_IN GABA_NNP as_IN a_DT potential_JJ site_NN for_IN teratogen_NN
        activity_NN for_IN VA_NNP and_CC other_JJ teratogens_NNS has_VBZ been_VBN little_RB
        explored_JJ ._. Preliminary_JJ reports_NNS have_VBP linked_VBN ligands_NNS active_JJ at_IN
        the_DT GABA_NNP receptor_NN with_IN SB_NNP or_CC other_JJ NTDs_NNP ,_, including_VBG
        benzodiazepines_NNS ,_, alcohol_NN ,_, and_CC zinc_NN [_NN 7_CD 8_CD 9_CD 10_CD 11_CD ]_NN ._.
        Preliminary_JJ work_NN from_IN this_DT laboratory_NN has_VBZ shown_VBN the_DT GABAa_NNP
        receptor_NN agonist_NN muscimol_NN and_CC the_DT GABAb_NNP agonist_NN baclofen_NN
        produce_VBP both_DT SB_NNP and_CC the_DT Arnold-_NNP Chiari_NNP malformation_NN ,_,
        commonly_RB associated_VBN with_IN SB_NNP [_NN 12_CD 13_CD 14_CD ]_NN ._. VA_NNP appears_VBZ to_TO
        produce_VB most_JJS of_IN its_PRP$ anticonvulsant_NN effects_NNS by_IN increasing_VBG
        levels_NNS of_IN GABA_NNP in_IN the_DT CNS_NNP ,_, presumably_RB by_IN inhibiting_VBG the_DT
        enzyme_NN GABA-transaminase_NNP (_( GABA-T_NNP )_) ._. There_EX is_VBZ other_JJ evidence_NN
        to_TO suggest_VB that_IN substances_NNS which_WDT alter_VBP the_DT function_NN of_IN the_DT
        GABAergic_NNP system_NN may_MD contribute_VB to_TO the_DT formation_NN of_IN NTDs_NNP ._.
        Alcohol_NNP has_VBZ been_VBN associated_VBN with_IN NTDs_NNP [_NN 11_CD ]_NN and_CC is_VBZ known_VBN
        to_TO enhance_VB the_DT functioning_NN of_IN GABA_NNP ._. Benzodiazepines_NNP (_( BDZs_NNP )_) ,_,
        which_WDT enhance_VB the_DT activity_NN of_IN the_DT GABA_NNP receptor_NN ,_, also_RB
        enhance_VB the_DT teratogenic_JJ effects_NNS of_IN VA_NNP in_IN humans_NNS [_NN 10_CD ]_NN ._.
        Chlordiazepoxide_NNP ,_, another_DT BDZ_NNP ,_, has_VBZ been_VBN shown_VBN to_TO produce_VB
        NTDs_NNP in_IN the_DT hamster_NN [_NN 11_CD ]_NN ._.
        Further_RB support_NN for_IN the_DT contention_NN that_IN VA_NNP may_MD produce_VB
        NTDs_NNP by_IN way_NN of_IN GABA_NNP activity_NN include_VBP the_DT following_VBG
        evidence_NN ._. One_CD hypothesis_NNS of_IN VAs_NNP mechanism_NN of_IN action_NN holds_VBZ
        that_IN it_PRP alters_NNS intracelluar_NN pH_NN ._. This_DT may_MD be_VB the_DT case_NN as_IN
        GABA_NNP can_MD increase_VB intracellular_NN proton_NN levels_NNS by_IN
        intensifying_VBG bicarbonate_NN ion_NN conductance_NN through_IN a_DT
        GABA-gated_NNP channel_NN [_NN 15_CD ]_NN which_WDT may_MD act_VB as_RB a_DT "_'' developmental_NN
        handshake_NN "_'' and_CC regulate_VB neuronal_NN differentiation_NN [_NN 16_CD ]_NN ._.
        The_DT chloride_NN channel_NN ,_, an_DT integral_JJ part_NN of_IN the_DT GABA_NNP a_DT
        receptor_NN ,_, has_VBZ been_VBN implicated_VBN in_IN embryonic_JJ development_NN [_NN 17_CD
        ]_NN ._. GABA_NNP receptors_NNS are_VBP first_RB seen_VBN at_IN the_DT time_NN the_DT neural_NN
        tube_NN formation_NN [_NN 18_CD ]_NN ._. Binding_NNP sites_NNS to_TO GABA_NNP agonists_NNS and_CC
        antagonists_NNS and_CC the_DT expression_NN of_IN GABA_NNP receptor_NN mRNAs_NNS are_VBP
        seen_VBN starting_VBG at_IN 4_CD days_NNS of_IN development_NN and_CC peak_NN at_IN 10_CD -_: 15_CD
        days_NNS ,_, corresponding_JJ to_TO the_DT time_NN of_IN neural_NN tube_NN formation_NN [_NN
        19_CD ]_NN ._. Many_JJ neurotransmitters_NNS ,_, including_VBG GABA_NNP ,_, are_VBP growth_NN
        factor_NN candidates_NNS for_IN the_DT CNS_NNP [_NN 20_CD 21_CD 22_CD ]_NN ._.
        Based_VBN on_IN the_DT above_JJ information_NN we_PRP have_VBP undertaken_VBN this_DT
        study_NN to_TO systematically_RB examine_VB the_DT effects_NNS of_IN GABA_NNP
        agonists_NNS and_CC antagonists_NNS at_IN both_DT the_DT GABA_NNP a_DT and_NN b_SYM receptor_NN
        and_CC the_DT role_NN they_PRP may_MD play_VB in_IN SB_NNP ._. We_PRP used_VBD an_DT established_VBN
        model_NN of_IN SB_NNP in_IN the_DT rat_NN to_TO test_VB the_DT hypothesis_NNS using_VBG VA_NNP as_IN a_DT
        known_VBN standard_JJ ._. This_DT model_NN of_IN SB_NNP uses_VBZ the_DT width_NN of_IN the_DT
        vertebral_NN arch_VBP as_IN an_DT indicator_NN of_IN neural_NN tube_NN closure_NN ._.
        While_IN this_DT model_NN does_VBZ not_RB produce_VB a_DT specific_JJ SB_NNP lesion_NN the_DT
        widening_NN of_IN the_DT vertebral_NN arch_VBP provides_VBZ a_DT model_NN that_WDT
        resembles_VBZ human_JJ SB_NNP in_IN terms_NNS of_IN accompanying_VBG defects_NNS [_NN 12_CD 13_CD
        14_CD 23_CD ]_NN and_CC response_NN to_TO folate_NN and_CC other_JJ drugs_NNS [_NN 6_CD 11_CD 24_CD 25_CD
        ]_NN and_CC meets_VBZ the_DT formal_JJ definition_NN of_IN a_DT neural_NN tube_NN defect_NN :_:
        any_DT defect_NN in_IN the_DT covering_NN of_IN the_DT central_JJ nervous_JJ
        system_NN ._.
        We_PRP report_VBP here_RB the_DT effects_NNS of_IN GABA_NNP a_DT and_NN b_SYM receptor_NN
        agonists_NNS and_CC antagonists_NNS administered_VBN to_TO rats_NNS at_IN 10_CD days_NNS
        gestation_NN ,_, the_DT period_NN of_IN neural_NN tube_NN formation_NN ._.
      
      
        Results_NNS and_CC Discussion_NNP
        A_DT total_NN of_IN 1156_CD embryos_NNS from_IN 123_CD litters_NNS were_VBD examined_VBN ._.
        Measurements_NNP from_IN the_DT embryos_NNS were_VBD averaged_VBN for_IN each_DT litter_NN
        and_CC the_DT litter_NN was_VBD used_VBN as_IN the_DT unit_NN of_IN analysis_NN ._. All_DT
        measurements_NNS were_VBD made_VBN in_IN a_DT blind_JJ manner_NN ._. ANOVA_NNP revealed_VBD a_DT
        significant_JJ effect_NN of_IN drug_NN treatment_NN of_IN the_DT average_JJ
        vertebral_NN arch_VBP distance_NN (_( F_NN (_( 13_CD ,_, 109_CD )_) =_SYM 7_CD ._. 70_CD ,_, p_NN <_NN ._. 0001_CD )_) ._.
        The_DT Bonferroni_NNP test_NN was_VBD used_VBN for_IN follow-up_JJ comparisons_NNS and_CC
        the_DT comparisons_NNS to_TO the_DT normal_JJ saline_NN group_NN are_VBP given_VBN below_IN
        and_CC in_IN Table_NNP 1_CD and_CC in_IN Figure_NN 1_CD where_WRB the_DT results_NNS are_VBP
        presented_VBN graphically_RB ._. Occasionally_RB other_JJ defects_NNS were_VBD
        noted_VBN in_IN the_DT embryos_NNS ,_, chiefly_RB fused_JJ ribs_NNS ,_, these_DT defects_NNS
        were_VBD not_RB appreciable_JJ and_CC did_VBD not_RB impact_VB the_DT vertebral_NN arch_VBP
        analysis_NN ._. There_EX is_VBZ no_DT statistically_RB significant_JJ
        relationship_NN between_IN mean_NN vertebral_NN arch_VBP distance_NN and_CC mean_VB
        littler_NN size_NN ._.
        Valproic_NNP Acid_NNP produced_VBD a_DT significant_JJ widening_NN of_IN the_DT
        vertebral_NN arch_VBP in_IN a_DT manner_NN consistent_JJ with_IN previous_JJ reports_NNS
        (_( p_NN <_NN ._. 0005_CD )_) [_NN 6_CD 24_CD ]_NN
        The_DT GABAa_NNP agonist_NN muscimol_NN produced_VBD a_DT significant_JJ
        widening_NN of_IN the_DT vertebral_NN arch_VBP at_IN all_DT three_CD doses_NNS tested_VBN
        (_( 1_CD ,_, 2_CD ,_, 4_CD mg_NN /_NN kg_NN )_) (_( p_NN =_SYM ._. 06_CD for_IN 1_CD mg_NN /_NN kg_NN ,_, p_NN <_NN ._. 05_CD for_IN 2_CD &_CC
        4_CD mg_NN /_NN kg_NN )_) ._. The_DT GABAa_NNP antagonist_NN bicuculline_NN also_RB widened_VBD
        vertebral_NN arch_VBP distance_NN at_IN the_DT 0_CD ._. 5_CD and_CC 1_CD mg_NN /_NN kg_NN doses_NNS (_( p_NN
        <_NN ._. 05_CD )_) ,_, but_CC not_RB at_IN the_DT 2_CD mg_NN /_NN kg_NN dose_NN ._.
        The_DT GABAb_NNP agonist_NN baclofen_NN produced_VBD significant_JJ widening_NN
        of_IN the_DT vertebral_NN arch_VBP at_IN 30_CD mg_NN /_NN kg_NN (_( p_NN <_NN ._. 05_CD )_) but_CC not_RB at_IN
        15_CD or_CC 60_CD mg_NN /_NN kg_NN ._. The_DT GABAb_NNP antagonist_NN hydroxysaclofen_NN
        produced_VBD a_DT significant_JJ narrowing_NN of_IN the_DT vertebral_NN arch_VBP at_IN
        all_DT three_CD doses_NNS tested_VBN (_( p_NN =_SYM ._. 09_CD for_IN 1_CD mg_NN /_NN kg_NN ,_, p_NN =_SYM ._. 001_CD for_IN 3_CD
        mg_NN /_NN kg_NN and_CC p_NN =_SYM ._. 05_CD for_IN 5_CD mg_NN /_NN kg_NN )_) ._.
        This_DT study_NN indicates_VBZ that_WDT substances_NNS active_JJ at_IN either_DT
        the_DT GABA_NNP a_DT or_CC b_SYM receptors_NNS have_VBP teratogenic_JJ potential_NN ._. The_DT
        most_RBS striking_JJ feature_NN of_IN the_DT drug_NN effects_NNS is_VBZ the_DT
        differential_NN effect_NN of_IN antagonizing_VBG the_DT GABAb_NNP receptor_NN with_IN
        hydroxysaclofen_NN ._. While_IN the_DT GABAa_NNP agonist_NN muscimol_NN and_CC
        antagonist_NN bicucullin_NN widened_VBD the_DT vertebral_NN arch_VBP ,_, as_IN did_VBD
        the_DT GABAb_NNP agonist_NN baclofen_NN ,_, the_DT GABAb_NNP antagonist_NN
        hydroxysaclofen_NN narrowed_VBD the_DT vertebral_NN arch_VBP ._. Narrowing_VBG of_IN
        the_DT vertebral_NN arch_VBP was_VBD unexpected_JJ but_CC has_VBZ been_VBN previously_RB
        reported_VBN ._. Previous_JJ work_NN in_IN this_DT laboratory_NN has_VBZ demonstrated_VBN
        narrowing_NN of_IN the_DT vertebral_NN arch_VBP when_WRB zinc_NN is_VBZ
        co-administered_JJ with_IN baclofen_NN or_CC muscimol_NN [_NN 13_CD ]_NN ._. It_PRP is_VBZ
        unclear_JJ what_WP the_DT structural_JJ or_CC functional_JJ consequence_NN of_IN
        vertebral_NN arch_VBP narrowing_NN is_VBZ ._. Work_NN in_IN this_DT laboratory_NN has_VBZ
        shown_VBN lags_VBZ in_IN neuromuscular_NN development_NN associated_VBN with_IN
        excessive_JJ zinc_NN exposure_NN during_IN neural_NN tube_NN formation_NN and_CC ,_,
        possibly_RB ,_, accompanying_VBG narrowing_NN of_IN the_DT vertebral_NN arches_NNS [_NN
        26_CD ]_NN ._. Another_DT curious_JJ finding_NN of_IN this_DT study_NN is_VBZ that_DT
        widening_NN of_IN the_DT vertebral_NN arch_VBP occurs_VBZ with_IN either_DT the_DT GABAa_NNP
        agonist_NN muscimol_NN or_CC the_DT antagonist_NN bicuculline_NN ._. In_IN classic_JJ
        pharmacology_NN it_PRP would_MD be_VB expected_VBN that_IN the_DT effects_NNS would_MD be_VB
        opposite_JJ ._. However_RB ,_, in_IN this_DT instance_NN it_PRP may_MD be_VB that_IN any_DT
        disruption_NN of_IN the_DT normal_JJ function_NN of_IN the_DT GABAa_NNP receptor_NN and_CC
        its_PRP$ integral_JJ chloride_NN channel_NN result_NN in_IN widening_NN of_IN the_DT
        vertebral_NN arch_VBP ._. On_IN the_DT other_JJ hand_NN the_DT GABAb_NNP receptor_NN is_VBZ not_RB
        directly_RB linked_VBN to_TO a_DT chloride_NN channel_NN exerting_VBG its_PRP$ effect_NN
        via_IN second_JJ messenger_NN systems_NNS ._. This_DT functional_JJ difference_NN
        may_MD allow_VB for_IN a_DT classic_JJ agonist-antagonist_JJ drug_NN effect_NN
        during_IN neural_NN tube_NN formation_NN ._.
        One_CD potential_JJ confound_NN of_IN this_DT study_NN is_VBZ the_DT role_NN of_IN
        developmental_NN delays_NNS ._. Animals_NNS exposed_VBN to_TO valproate_NN and_CC
        presumably_RB suffering_VBG from_IN widened_VBD vertebral_NN arches_NNS can_MD show_VB
        weight_NN differences_NNS well_RB into_IN post-natal_JJ life_NN ._. However_RB ,_,
        behavioral_JJ differences_NNS persist_VBP even_RB when_WRB weight_NN differences_NNS
        no_RB longer_RB exist_VB [_NN 1_CD ]_NN ._. However_RB ,_, we_PRP are_VBP unaware_JJ of_IN any_DT
        studies_NNS directly_RB examining_VBG the_DT spinal_JJ columns_NNS of_IN animals_NNS
        well_RB into_IN post-natal_JJ life_NN ,_, therefore_RB it_PRP is_VBZ unclear_JJ if_IN the_DT
        widening_NN of_IN the_DT vertebral_NN arch_VBP seen_VBN at_IN 21_CD days_NNS persists_VBZ ._.
        Another_DT limitation_NN to_TO this_DT study_NN is_VBZ the_DT small_JJ sample_NN sizes_NNS
        for_IN some_DT groups_NNS and_CC the_DT administration_NN of_IN drugs_NNS to_TO only_RB one_CD
        day_NN ._. These_DT results_NNS need_VBP to_TO be_VB replicated_VBN using_VBG larger_JJR
        sample_NN sizes_NNS and_CC administering_VBG the_DT drugs_NNS at_IN other_JJ times_NNS
        during_IN gestation_NN ._. It_PRP is_VBZ possible_JJ that_IN these_DT drugs_NNS may_MD
        disrupt_VB neural_NN tube_NN formation_NN if_IN given_VBN outside_IN of_IN the_DT
        classic_JJ time_NN frame_NN for_IN neural_NN tube_NN formation_NN ._.
        GABA_NNP is_VBZ a_DT well-documented_JJ neurotrophic_JJ agent_NN involved_VBN in_IN
        brain_NN development_NN [_NN 27_CD 28_CD 29_CD 30_CD ]_NN ._. Most_JJS of_IN the_DT work_NN done_VBN
        on_IN the_DT effects_NNS of_IN GABA_NNP and_CC neural_NN development_NN has_VBZ been_VBN done_VBN
        on_IN embryos_NNS and_CC embryonic_JJ tissue_NN well_RB past_JJ the_DT neural_NN tube_NN
        stage_NN [_NN 27_CD 31_CD 32_CD ]_NN ._. However_RB ,_, there_EX is_VBZ evidence_NN of_IN glutamic_JJ
        acid_NN decarboxylase_NN (_( GAD_NNP )_) and_CC GABA_NNP receptor_NN expression_NN about_IN
        the_DT time_NN of_IN neural_NN tube_NN formation_NN [_NN 27_CD ]_NN ._. Given_VBN that_IN GABA_NNP
        is_VBZ important_JJ to_TO neural_NN development_NN ,_, and_CC the_DT early_JJ
        developmental_NN time_NN frame_NN of_IN the_DT GABA_NNP system_NN ,_, it_PRP is_VBZ logical_JJ
        that_WDT agents_NNS active_JJ at_IN the_DT GABA_NNP receptor_NN (_( ethanol_NN ,_, BDZs_NNP )_) can_MD
        have_VB adverse_JJ consequences_NNS on_IN CNS_NNP development_NN ._. Nearly_RB all_DT of_IN
        the_DT substances_NNS examined_VBD are_VBP GABAa_NNP receptor_NN ligands_NNS ._. GABAb_NNP
        receptor_NN effects_NNS have_VBP been_VBN little_RB studied_VBN and_CC the_DT role_NN of_IN
        the_DT GABAb_NNP receptor_NN in_IN neural_NN development_NN is_VBZ little_RB known_VBN
        and_CC should_MD be_VB more_RBR thoroughly_RB investigated_VBN ._.
      
      
        Conclusions_NNP
        GABA_NNP may_MD play_VB an_DT important_JJ role_NN in_IN neural_NN tube_NN formation_NN
        and_CC the_DT production_NN of_IN neural_NN tube_NN defects_NNS ._. Substances_NNP
        active_JJ at_IN the_DT GABA_NNP a_DT or_CC b_SYM receptor_NN may_MD be_VB potentially_RB
        teratogenic_JJ ._. In_IN particular_JJ ,_, the_DT findings_NNS indicate_VBP that_IN GABA_NNP
        a_DT or_CC b_SYM ligands_NNS are_VBP capable_JJ of_IN altering_VBG neural_NN formation_NN ._.
        GABA_NNP may_MD play_VB a_DT greater_JJR than_IN appreciated_VBN role_NN in_IN neural_NN
        tube_NN formation_NN and_CC may_MD be_VB important_JJ in_IN neural_NN tube_NN defects_NNS ._.
        The_DT narrowing_NN of_IN the_DT vertebral_NN arch_VBP produced_VBN by_IN the_DT GABA_NNP b_SYM
        antagonist_NN hydroxysalcofen_NN suggests_VBZ that_IN GABA_NNP b_SYM receptor_NN
        may_MD play_VB an_DT important_JJ ,_, but_CC undefined_JJ role_NN in_IN neural_NN tube_NN
        closure_NN that_WDT differs_VBZ from_IN the_DT GABA_NNP a_DT receptor_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Reference_NNP groups_NNS
          Normal_NNP saline_NN intraperitoneally_RB (_( IP_NNP )_) 0_CD ._. 9_CD cc_NN to_TO
          establish_VB baseline_NN ._.
          Valproic_NNP acid_NN subcutaneously_RB (_( SC_NNP )_) 1200_CD mg_NN /_NN kg_NN (_( 600_CD
          mg_NN /_NN cc_NN )_) in_IN two_CD divided_VBN doses_NNS over_IN 8_CD hours_NNS ._. Previous_JJ
          studies_NNS have_VBP shown_VBN this_DT dose_NN and_CC route_NN to_TO reliably_RB
          produce_VB SB_NNP in_IN the_DT rat_NN [_NN 24_CD ]_NN ._. This_DT group_NN provided_VBD a_DT
          positive_JJ control_NN to_TO which_WDT the_DT teratogenic_JJ activity_NN of_IN
          other_JJ substances_NNS could_MD be_VB compared_VBN ._.
        
        
          GABAa_NNP test_NN groups_NNS
          Muscimol_NNP IP_NNP at_IN 1_CD ,_, 2_CD ,_, or_CC 4_CD mg_NN /_NN kg_NN (_( 1_CD mg_NN /_NN cc_NN )_) ._. Muscimol_NNP is_VBZ
          a_DT well-documented_JJ specific_JJ and_CC potent_JJ GABAa_NNP agonist_NN [_NN 33_CD
          ]_NN ._.
          Bicuculline_NNP methiodide_NN IP_NNP at_IN 0_CD ._. 5_CD ,_, 1_CD or_CC 2_CD mg_NN /_NN kg_NN (_( 1_CD
          mg_NN /_NN cc_NN )_) ._. Bicuculline_NNP is_VBZ a_DT well-documented_JJ specific_JJ and_CC
          potent_JJ GABAa_NNP antagonist_NN [_NN 33_CD ]_NN ._.
        
        
          GABAb_NNP test_NN groups_NNS
          Baclofen_NNP IP_NNP at_IN 15_CD ,_, 30_CD ,_, or_CC 60_CD mg_NN /_NN kg_NN (_( 9_CD mg_NN /_NN cc_NN as_IN aqueous_JJ
          suspension_NN )_) ._. Baclofen_NNP is_VBZ a_DT well-documented_JJ and_CC specific_JJ
          GABAb_NNP agonist_NN [_NN 34_CD ]_NN ._.
          Hydroxysaclofen_NNP IP_NNP at_IN 1_CD ,_, 3_CD ,_, or_CC 5_CD mg_NN /_NN kg_NN (_( 1_CD mg_NN /_NN cc_NN )_) ._.
          Hydroxysaclofen_NNP is_VBZ a_DT well-documented_JJ specific_JJ and_CC potent_JJ
          GABAb_NNP antagonist_NN [_NN 34_CD ]_NN ._.
        
        
          Embryo_NN studies_NNS
          After_IN injection_NN gestation_NN was_VBD allowed_VBN to_TO otherwise_RB
          progress_VB as_IN normal_JJ ._. At_IN 21_CD days_NNS gestation_NN the_DT females_NNS were_VBD
          euthenized_JJ with_IN chloroform_NN ,_, the_DT abdomen_NN opened_VBD and_CC the_DT
          uterus_NN and_CC uterine_NN contents_NNS removed_VBN ._. Fetuses_NNP were_VBD removed_VBN
          and_CC had_VBN their_PRP$ abdomens_NNS opened_VBD to_TO allow_VB for_IN the_DT
          penetration_NN of_IN 10_CD %_NN 0_CD ._. 1_CD M_NNP phosphate_NN buffered_JJ formalin_NN in_IN
          which_WDT they_PRP were_VBD immersed_VBN ._. After_IN three_CD days_NNS fixation_NN the_DT
          fetuses_NNS were_VBD stained_JJ for_IN bone_NN and_CC cartilage_NN as_IN described_VBN
          previously_RB [_NN 24_CD ]_NN ._. Briefly_NNP ,_, the_DT fetuses_NNS were_VBD eviscerated_JJ
          and_CC skinned_JJ ._. Cartilage_NNP was_VBD stained_JJ with_IN alcian_NN blue_JJ
          followed_VBN by_IN bone_NN staining_VBG with_IN alizarin_NN red_JJ ._. The_DT fetuses_NNS
          were_VBD cleared_VBN in_IN KOH_NNP and_CC graded_JJ concentrations_NNS of_IN
          glycerol_NN ._.
          After_IN clearing_VBG the_DT fetuses_NNS were_VBD inspected_VBN with_IN a_DT
          dissecting_VBG microscope_NN and_CC the_DT width_NN of_IN the_DT vertebral_NN arch_VBP
          gap_NN was_VBD measured_VBN with_IN an_DT eyepiece_NN micrometer_NN from_IN T-_NNP 9_CD to_TO
          S-_NNP 4_CD ._. Previous_JJ work_NN has_VBZ shown_VBN that_IN these_DT vertebrae_NN are_VBP the_DT
          most_RBS clearly_RB visible_JJ and_CC the_DT most_RBS frequently_RB effected_JJ [_NN 6_CD
          24_CD ]_NN ._. For_IN the_DT sake_NN of_IN clarity_NN vertebral_NN arch_VBP distances_NNS
          from_IN T-_NNP 9_CD to_TO S-_NNP 4_CD were_VBD averaged_VBN for_IN the_DT each_DT embryo_NN ._.
          For_IN analysis_NN vertebral_NN arch_VBP distance_NN was_VBD averaged_VBN for_IN
          each_DT fetus_NN and_CC then_RB for_IN the_DT litter_NN ._. Data_NNP was_VBD analyzed_VBN
          with_IN Analysis_NNP of_IN Variance_NNP with_IN follow-up_JJ statistics_NNS
          (_( Bonferroni_NNP test_NN )_) using_VBG Statview_NNP 5_CD ._. 0_CD for_IN the_DT
          Macintosh_NNP ._.
        
      
    
  
